1. Draw 2 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL total (2.5 mg/mL each), 1 unit = 0.01 mL » 50 mcg total, 25 mcg each peptide, on a U-100 insulin syringe.

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29 amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5 to 2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.

Observations from preclinical and clinical literature.

• Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
• Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
• Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
• Generally well tolerated; possible transient effects may include flushing, headache, or injection-site
  reactions.
• Some individuals report increased appetite, water retention, or tingling sensations.